Last reviewed · How we verify

NCT05701293: CURRENT

A ProspeCtive mUlticenteR Investigation on RENzar Stent Safety and Efficacy in the Treatment of Patients With Femoro-popliteal Disease in Tuscany (CURRENT Registry)

Recruiting now Last updated 20 July 2023
What this trial tests

trial testing Endovascular implantation of Renzan Stent in Peripheral Arterial Disease in 100 participants. Currently enrolling.

Timeline
1 December 2022
Primary endpoint
1 December 2023
1 December 2026

Quick facts

Lead sponsorAzienda Ospedaliera Universitaria Senese
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date1 December 2022
Primary completion1 December 2023
Estimated completion1 December 2026
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliera Universitaria Senese — full company profile →

Who can join

18 and older, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CURRENT Registry is a physician-initiated prospective, multicenter, post-market, single-arm study with a plan to include approximately 100 patients eligible to be treated with RenzanTM Peripheral Stent System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Azienda Ospedaliera Universitaria Senese trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05701293.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing